Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Effectiveness of the selection of administered 131I-iodide activity based on the thyroid "volume algorithm" approach for the therapy of Graves' disease

Federica Guidoccio, Antonio Claudio Traino, Federica Orsini, Duccio Volterrani, Giuliano Mariani, Mariano Grosso.




Abstract

Background: In the current clinical practice, radiometabolic therapy of Graves' disease is based on the administration of an amount of 131I-iodide defined according to two different modalities: administration of a fixed activity (up to a maximum of 555 MBq allowed by many national legislations on an outpatient basis) or an 131I-iodide activity individually defined so as to reach the certain fixed values of target thyroid-absorbed dose. The aim of this study was to prove the effectiveness of a personalized approach to cure Graves' disease based on the administration of a 131I activity defined according to the desired "optimal final thyroid mass." According to this model, one can predict the thyroid-absorbed dose following the administration of an activity as a function of the desired reduction of the baseline, pre-treatment mass of the gland.
Methods: A total of 217 patients with Graves' disease were included in this study. They were randomly divided into five groups, of which four groups were divided based on fixed thyroid-absorbed dose value of 100 (Group A, n = 29), 200 (Group B, n = 25), 300 (Group C, n = 51), and 400 (Group D, n = 25), respectively, whereas patients of the final thyroid mass (mf) (Group V, n = 87) received a 131I activity calculated based on the desired "optimal" final thyroid mass according to the so-called "volume algorithm" approach.
Results: At the 1-year follow-up, therapeutic success (i.e., a state of either hypothyroidism or euthyroidism) was achieved in 48% of patients in Group A (100 Gy), 64% in Group B (200 Gy), 78% in Group C (300 Gy), 96% in Group D (400 Gy), and 92% in Group V (mf). A significantly higher proportion of patients were was cured in Groups D and V (mf) than in Groups A, B, and C (P < 0.01). There was no statistical difference in cure rates between Groups D and V (mf). The median thyroid-absorbed dose was 407 Gy for Group D (400 Gy), significantly higher than 296 Gy for Group V (mf) (P < 0.001) and also significantly greater than the administered 131I activity (494 vs. 345 MBq, P < 0.001).
Conclusions: This study indicates that the most effective thyroid-absorbed dose to be delivered for the radiometabolic therapy of patients with Graves' disease should not be based on a fixed dose but rather should be personalized. The new method based on thyroid mass reduction allows the optimization of 131I-iodide therapy for Graves' disease on an individual basis, achieving a high therapeutic efficacy while at the same time avoiding the administration of unjustified greater activities of 131I.

Key words: Graves' disease, hyperthyroidism, radioiodine; 131I-iodide, dosimetry in Graves' disease, "Volume algorithm" approach






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.